Cowen and Company’s Eli Lilly LLY Stock Holding History

Cowen and Company’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-130,399	Closed	-$116M	–	181
2024 Q3	$116M	Buy	+130,399	New	+$117M	3.89%	8

Other funds holding LLY

Lilly Endowment Indiananapolis, Indiana $84.5B AUM 11.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Cowen and Company's LLY Position: Q4 2024 in Review

Cowen and Company sold out of Eli Lilly (LLY) in Q4 2024, closing a stake of 130,399 shares — an estimated $116M sold.

Cowen and Company first reported a position in LLY in Q3 2024 and held it in 1 quarter. The position peaked at $116M in Q3 2024. 3,906 funds tracked by Wall St. Rank hold LLY as of Q4 2024.

Cowen and Company reported no remaining Eli Lilly position as of Q4 2024 after selling out during the quarter.
Cowen and Company sold 130,399 Eli Lilly shares in Q4 2024, an estimated $116M.
Cowen and Company first reported a position in Eli Lilly in Q3 2024 and held it in 1 quarter.
Cowen and Company's Eli Lilly position peaked at $116M in Q3 2024.
3,906 funds tracked by Wall St. Rank held Eli Lilly as of Q4 2024.

Based on Cowen and Company's 13F filing for Q4 2024.